drugset
drugset / Trial / NCT03871439

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

NCT03871439 ↗

Phase 1 Completed 10 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to characterize the plasma pharmacokinetics of two formulations of PF 05221304 in healthy adults.

Timeline

Start
2019-03-13
Primary completion
2019-05-08
Completion
2019-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Clesacostat Small molecule 50 mg Oral

Indications

No indication recorded.